Cite
HARVARD Citation
Yang, J. et al. (n.d.). 1381PDGefitinib with or without pemetrexed in nonsquamous (NS) non-small cell lung cancer (NSCLC) with EGFR mutation (mut): Final overall survival (OS) results from a randomized phase II study. Annals of oncology. p. . [Online].